Annals of Internal Medicine

LETTERS

OBSERVATION: CASE REPORT

Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19

Background: A subset of patients with coronavirus disease 2019 (COVID-19) will develop acute respiratory distress syndrome and require mechanical ventilation. Studies suggest that many patients with COVID-19 and acute respiratory distress syndrome experience a cytokine storm characterized by fever; hyperferritinemia; and a massive release of inflammatory cytokines, including interleukin-6, tumor necrosis factor- α , and monocyte chemoattractant proteins (1). These findings led to the hypothesis that biological agents targeting specific cytokine or inflammatory pathways may improve the respiratory outcomes of patients with the most severe forms of COVID-19 (2).


Objective: To describe a patient with COVID-19 and overt hemophagocytic syndrome whose response to treatment was consistent with this hypothesis.

Case Report: A 51-year-old man who had received a kidney transplant was referred to our intensive care unit for cough, fever, and shortness of breath leading to the presumptive diagnosis of COVID-19. On day 1, acute respiratory failure

required mechanical ventilation and prone positioning. Therapy with dexamethasone (5 mg twice daily), ceftriaxone (2 q/d), and spiramycin (1.5 million units 3 times daily) was initiated. Tacrolimus and mycophenolate mofetil were withdrawn. On day 2, the patient developed refractory multiorgan failure characterized by an inflammatory state, heart failure, stage 3 acute-on-chronic kidney injury, acute liver failure, nonregenerative anemia, thrombocytopenia, and lactic acidosis. The C-reactive protein level was 262 mg/L, and the ferritin level was 52 005 µg/L. We considered a diagnosis of hemophagocytic syndrome because the patient had underlying immunosuppression; fever of 39 °C; a serum ferritin level above 6000 µg/L; a hemoglobin level below 92 g/L; a platelet count below 110 × 10⁹ cells/L; high levels of serum triglycerides; and aspartate aminotransferase with an HScore of 253, which indicated that the probability of having hemophagocytic syndrome was 99.5% (3). Bone marrow aspiration and liver biopsy confirmed the presence of hemophagocytosis (Figure). Polymerase chain reaction identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in bronchoalveolar fluid (cycle threshold 21) and blood.

Given the salutary effects of interleukin-6 receptor inhibition in the treatment of secondary hemophagocytic syndromes (4) and chimeric antigen receptor T cell-related cyto-

Figure. Bone marrow and liver hemophagocytosis in a kidney transplant recipient with COVID-19.



COVID-19 = coronavirus disease 2019. A. Hemophagocytosis of polymorphonuclear neutrophils (*yellow arrow*), erythrocytes (*green arrow*), and platelets (*red arrow*) by activated macrophages in the bone marrow aspirate. May-Grünwald-Giemsa staining, original magnification × 1000. B. Kupffer cell hypertrophy and hyperplasia with hemophagocytosis of polymorphonuclear neutrophils (*yellow arrow*) and lymphocytes (*red arrow*) in the liver (hematoxylin-eosin staining). C. CD68 immunostaining of the liver biopsy (brown staining: activated macrophages with hemophagocytosis of erythrocytes (*green arrow*).

This article was published at Annals.org on 18 May 2020.

Letters

Table. Clinical and Laboratory Findings*

Finding	Days From Hospital Admission							Normal Range
	0	1	2	4	6	8	12	
Clinical								
Respiratory status	SB	VCC/PP	VCC	VCC	VCC	VCC	SB-PS	-
PaO ₂ -FIO ₂ ratio	-	109	236	271	294	283	290	>300
Norepinephrine dose, µg/kg/min	0	0.4	0.33	0.05	0.009	0	0	-
Laboratory								
Leukocyte count, × 10 ⁹ cells/L	11.8	9.9	18.8	22.5	16.6	26.4	24.3	4-10
Platelet count, $\times 10^{9}$ cells/L	121	125	94	73	40	64	38	150-450
Hemoglobin level, g/L	119	103	86	97	92	104	117	130-175
Aspartate aminotransferase level, U/L	63	-	>7000	5119	282	87	53	0-50
Serum creatinine concentration								
µmol/L	423	463	RRT	RRT	RRT	RRT	231	<120
mg/dL	4.8	5.2	RRT	RRT	RRT	RRT	2.6	<1.4
High-sensitivity cardiac troponin I level, $\mu g/L$	240	283	1124	235	126	-	342	<14
Prothrombin time, s	15.8	20.8	36.5	52.5	20.6	18.2	16.4	<19
Fibrinogen level, g/L	8	6.4	4.8	3.5	2.7	2	2.4	2-4
Factor V, % of control plasma	-	61	24	15	51	-	102	70-120
Serum ferritin level, μg/L	657	-	52 005	32 965	4214	1946	849	30-400
High-sensitivity C-reactive protein level, mg/L	322	-	262	-	25	15	_	<5
Interleukin-6 concentration, pg/mL	-	-	199	-	-	2191	-	<10
Interleukin-8 concentration, pg/mL	-	-	60	-	-	107	_	<10
Monocyte chemoattractant protein-1 level, pg/mL	-	-	176	-	-	107	-	<10
Triglyceride level								
mmol/L	-	-	2.18	3.7	-	-	-	0.5-1.5
mg/dL	-	-	193	327	-	-	-	44-132

* Dexamethasone was given on days 1 and 2. Tocilizumab was given on day 2.

PP = prone position; RRT = renal replacement therapy; SB = spontaneous breathing; SB-PS = SB with pressure support; VCC = volume-controlled ventilation.

kine release syndromes (5), we treated the patient with tocilizumab (8 mg/kg intravenously, once) as salvage therapy, instead of etoposide, and we withdrew dexamethasone. Tocilizumab administration was followed by dramatic improvement of the respiratory, hemodynamic, and liver conditions and correction of the ferritin levels (**Table**). Three days after tocilizumab administration, we observed normalization of circulating levels of CD3⁻ CD16⁺ CD56⁺ natural killer cells and effector CD8⁺ CD56⁺ and CD8⁺ CD57⁺ perforin-positive, granzyme-positive T cells.

Discussion: In this report, we describe an immunocompromised patient with COVID-19 and a related hemophagocytic syndrome whom we treated with tocilizumab. The cytokine storm and multiorgan failure rapidly reversed, and the patient made a speedy recovery. On hospital day 30, the patient was breathing spontaneously with protective tracheotomy, and rehabilitation is ongoing. On the basis of this experience, we suggest that clinicians who have similar patients consider using drugs that inhibit interleukin-6 to treat these patients while waiting for the results of the randomized controlled trials that are now evaluating tocilizumab in patients with COVID-19 and respiratory failure.

Stanislas Faguer, MD, PhD Arnaud Del Bello, MD Florence Abravanel, PharmD, PhD Marie-Laure Nicolau-Travers, PhD Nassim Kamar, MD, PhD University Hospital of Toulouse Toulouse, France

Acknowledgment: The authors thank Dr. Emmanuel Treiner, Prof. Jacques Izopet, Dr. François Vergez, and Prof. Jannick Selves for their

help in obtaining accurate immunology, pathology, and virology analyses in the context of the COVID-19 crisis.

Disclosures: Disclosures can be viewed at www.acponline.org /authors/icmje/ConflictOfInterestForms.do?msNum=L20-0419.

Corresponding Author: Stanislas Faguer, MD, PhD, Département de Néphrologie et Transplantation d'organes, Unité de Réanimation, INSERM U1048 (équipe 12, I2MC), Hôpital Rangueil, 1, avenue Jean Poulhes, 31059 Toulouse Cedex, France; e-mail, faguer.s@chu -toulouse.fr.

doi:10.7326/L20-0419

References

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. [PMID: 31986264] doi:10.1016/S0140-6736(20)30183-5

2. Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020:105954. [PMID: 32234467] doi:10.1016/j.ijantimicag.2020.105954

3. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613-20. [PMID: 24782338] doi:10.1002/art.38690 4. Faguer S, Vergez F, Peres M, et al. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis [Letter]. Hematol Oncol. 2016;34:55-7. [PMID: 25312407] doi:10.1002/hon.2174

5. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124-e131. [PMID: 27632680] doi:10.1097/CCM .00000000002053